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The Role of COX Inhibition in the Prevention of Progression of Barrett’s Esophagus To
Esophageal Adenocarcinoma
Abstract
Background: Barrett’s esophagus is the most significant predictor of the development of
esophageal adenocarcinoma. The current treatment recommendation is a proton pump inhibitor
to control acid reflux, yet there remains a significant number of individuals who progress to
cancer. More can be done to prevent this progression.
Purpose: To this end, this paper seeks to answer the following PICO question: P: Patients with
Barrett’s esophagus not yet esophageal adenocarcinoma; I: Standard PPI treatment with the
addition of Aspirin; C: Standard PPI treatment only; O: Prevention of progression of Barrett’s
esophagus to esophageal adenocarcinoma.
Methods: A comprehensive literature review was conducted using PubMed, Sage Journals, and
Science Direct using the search terms Barrett’s esophagus treatment, Barrett’s esophagus aspirin,
esophageal cancer prevention aspirin, cancer prevention aspirin, and prostaglandin cancer.
Inclusion criteria were peer-reviewed, scholarly journals and studies published during or after
2017. Excluded from the search were meta-analyses and reviews.
Conclusions: Aspirin shows promise as a possible adjunctive treatment to proton pump
inhibitors. A long-term study is needed to specifically assess if adding aspirin will reduce
progression to adenocarcinoma while also assessing safety. Several biomarkers and tissue
pathologies are already available to risk stratify who could benefit from this add-on treatment.

Key Words: Barrett’s esophagus, aspirin, esophageal adenocarcinoma, EAC, BE
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Introduction
Barrett’s esophagus is the metaplastic change of esophageal squamous epithelium to
columnar epithelium. 1 This protective effect is in response to long-standing exposure to
stomach acids, a consequence of gastroesophageal reflux disease (GERD). 2 Singh helps to
explain the importance of surveillance and appropriate management of GERD and Barrett’s
esophagus in his 2019 article. He explains that although every case of esophageal cancer arises
from Barrett’s, only 90% of those with a new diagnosis of esophageal cancer had a previous
diagnosis of Barrett’s.

3

The more severe the symptoms of reflux, the higher the risk for the

development of adenocarcinoma of the esophagus. This link between GERD, Barrett’s
esophagus, and esophageal cancer has not yet been fully detailed but much evidence exists
describing the association between the three, along with other risk factors for adenocarcinoma
such as central obesity and smoking. 1
The NIH estimates approximately twenty percent of the US adult population has GERD,
defined as symptoms associated with gastric reflux at least twice a week. 4 In a 2015 study
published in Gastroenterology, S. Kroep, et. al. used modeling to predict the progression of
Barrett’s esophagus to esophageal adenocarcinoma. They demonstrated an annual progression
rate of 0.19%.

5

The NIH can give us the numbers from estimates by the American Cancer
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Society. In 2022 in the US, there will be an estimated 20,640 new cases of esophageal cancer,
16,410 deaths, and a 5-year survival rate of 20.6% after diagnosis.

6

The incidence of Barrett’s has been increasing over time and esophageal adenocarcinoma
with it. 7 Esophageal adenocarcinoma represents a significant problem in the US. With the
proposed chain of gastric reflux to Barrett’s esophagus to cancer, new methods of prevention of
the progression of Barrett’s must be explored.
One of the mechanisms that may be involved in the transformation of metaplastic cells to
adenocarcinoma is the overexpression of cyclooxygenase-2. Prostaglandin activity is a result of
inflammation. It is synthesized by cyclooxygenases both 1 and 2. 8 Prolonged inflammation, as
is seen in GERD and Barrett’s, results in the overproduction of prostaglandins via COX-2
activity. This, and the other markers of inflammation, have been implicated in the formation of
GI tumors. Indeed, histological examination of many tumors displays increased levels of
prostaglandins.

9

In their article Chemoprevention in Barrett’s esophagus and esophageal adenocarcinoma,
Alkhayyat et. al. explain the role acid reflux has in cancer, namely increased cell proliferation
and decreased cell apoptosis. 10 This is why proton pump inhibitors (PPIs) have been the
mainstay treatment through their mechanism of action, gastric acid suppression. The authors
note that PPIs alone may not be the most effective treatment. PPIs may increase cyclooxygenase
(COX)-2 expression, which as previously noted, plays a role in the development of
adenocarcinoma. 10 Recent evidence points towards ASA and NSAIDS playing a role in other
types of GI cancers. They act through inhibition in the COX pathway; COX-2 expression is
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increased in areas of the esophagus with Barrett’s and adenocarcinoma. COX is also associated
with proliferation, apoptosis, and angiogenesis in cancer. 10
Aspirin has been proposed as protective against esophageal adenocarcinoma by inhibiting
COX-1 and COX-2; a longer duration of use was associated with greater protective effects,
though interestingly there was no protective effect with Celecoxib. 11 This leads to the PICO
question to assess trials regarding the use of aspirin in the prevention of esophageal
adenocarcinoma.
P: Patients with Barrett’s esophagus not yet esophageal adenocarcinoma
I: Standard PPI treatment with the addition of Aspirin
C: Standard PPI treatment only
O: Prevention of progression of Barrett’s esophagus to esophageal adenocarcinoma

To answer this question, literature will be reviewed demonstrating prostaglandins' role in
cancer. Next, this review will focus prostaglandin’s specific role in Barrett’s Esophagus. Also
include are studies investigating aspirin as a possible preventative for certain types of cancers
then, specifically, its use in Barrett’s. Finally, this review will discuss the adverse effects aspirin
has demonstrated and why patients must be risk stratified when considering adding aspirin to
standard Barrett’s esophagus treatment. It is important to find a more effective strategy than
proton pump inhibitors alone to prevent the transformation of Barrett’s esophagus to high-grade
dysplasia or esophageal adenocarcinoma. To that aim, this review will examine the current
literature to establish whether aspirin should be added as an adjunct to PPIs in the presence of
Barrett’s esophagus.
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Methods
A literature review was conducted through the databases PubMed, Sage Journals, and
Science Direct. The search terms were Barrett’s esophagus treatment, Barrett’s esophagus
aspirin, esophageal cancer prevention aspirin, cancer prevention aspirin, and prostaglandin
cancer. Inclusion criteria were peer-reviewed, scholarly journals and studies published during or
after 2017. Excluded from the search were meta-analyses and reviews. Articles were obtained
from Augsburg’s Lindell Library.
Review of Literature
Prostaglandins play an important role in the human immune inflammatory response, their
production increasing during any inflammatory response to injury or illness. Their generation is
governed by two synthases known as cyclooxygenase or COX-1 and COX-2. 8 An overactive or
prolonged inflammatory response, and therefore prostaglandins, have been implicated in the
genesis of cancer.

12

This led to investigating what, if any, role prostaglandins play in cancer.

COX/prostaglandin in cancer
The first study reviewed was published in 2019 by Wong et al in Theranostics. The
authors sought to if prostaglandins play a role in the development of gastric carcinoma via DNA
hypermethylation. In this randomized and controlled trial, Gastric cancer cells were exposed to
either prostaglandin E2 (PGE2) or control for 48 hours to assess DNA methylation, histone
methylation, demethylation, acetylation, and deacetylation changes associated with epigenetic
changes. They then used genomic sequencing to assess for promotor hypermethylation patterns
seen in cancer in PGE2 treated cells. COX2 transgenic mice were used to assess for the same
epigenetic and DNA methylation patterns observed in vitro. Finally, they retrospectively
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analyzed 21 human tissue samples from patients who had undergone a placebo-controlled trial
with a COX2 inhibitor and who had gastric intestinal metaplasia, comparing them to 21 tissue
samples from the placebo group.

13

Wong et al found that DNA methylation was upregulated with PGE2 vs control in such a
way that indicates PGE2 can begin the DNA methylation process seen in other cancers. They
also found the activity of PGE2 was dose-dependent. PGE2 treated cells did demonstrate
increased promoter hypermethylation as seen in other cancer cells. Transgenic mice displayed
the same DNA methylation patterns found in cancer as compared to wild-type mice that did not.
The retrospectively assessed tissue samples showed the COX2 inhibitor treatment group did not
show DNA methylation patterns as did those in the placebo group. 13
While this study did not include human subjects it provides an important basis for the
mechanism prostaglandins play in the development of cancer cells. The sample size of
retrospectively assessed tissues was also very small but this does help to indicate further study on
the subject. It also leads to the next area of study, the role cyclooxygenases play in Barrett’s
esophagus itself.
COX in Barrett’s
I reviewed two studies regarding the role of cyclooxygenase-2 (COX-2) in Barrett’s
esophagus. The first was published in 2020 by Majka et al in the American Journal of
Physiology-Gastrointestinal and Liver Physiology. The authors investigated the interaction
between COX-2 and epidermal growth factors in the development of Barrett’s esophagus. They
used mice with a surgically created esophageal gastric duodenal anastomosis to introduce
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stomach acids to the esophagus to induce the damage seen in reflux. The rats were randomized
into several treatment groups to evaluate epidermal growth factors and several medications
including celecoxib and pantoprazole. After 3 months of treatment, rats were anesthetized and
their abdomens surgically opened. One of the samples collected and measured was esophageal
mucosal PGE2 generation. Esophageal mucosal damage was also measured macroscopically and
microscopically with blinded examiners. They graded the esophagus according to the degree of
lesions present and development of Barrett's, development of dysplasia of squamous cells, and
development of esophageal adenocarcinoma. The primary outcome showed that epidermal
growth factor decreased blood flow to the esophagus. These rats also expressed significantly
higher levels of COX-2. Rats treated with celecoxib (a COX-2 inhibitor), ranitidine, or
pantoprazole had significantly more blood flow. Combining celecoxib with other medications
significantly reduced dysplasia and mucosal damage compared to using the other medications
alone.

14

This study also used rat models instead of humans and had a relatively low number of

subjects. It also used celecoxib instead of aspirin but these medications both inhibit COX-2.
Using the rat models did allow researchers to dissect and thoroughly examine the esophagus for
the specific chemical markers this paper is investigating. It also reinforces the effectiveness of
proton pump inhibitors (PPIs) in the treatment of Barrett’s but also suggests there is a need for an
adjunct. The authors also demonstrated more severe esophageal mucosal damage led to more
COX-2 and prostaglandin expression, suggesting an avenue for adjunctive treatment.
I also reviewed an article from 2011 in Alimentary Pharmacology & Therapeutics. De
Bortoli et al. used a randomized clinical trial to compare two different PPIs in treating Barrett’s
esophagus. The researchers used three biochemical markers in their study, Ki67, COX-2, and
cell apoptosis, all associated with cancer.

15

They used 77 humans for this one-year trial, a small
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number but their study design was limited by both cost and finding enough participants that met
inclusion criteria at a single institution. The study found increased COX-2 expression in
esophageal samples of those that also had decreased cell apoptosis and increased Ki67, markers
of cancer the authors had previously established. 15 This is an older study, with a small and
homogenous sample size, occurring over a very short time. It also lacked in a control group
receiving a placebo. This study did use objective markers though and was able to demonstrate
significantly increased COX-2 in humans with Barrett’s esophagus. Now that prostaglandin and
COX-2 have been shown to have a role in the development of cancer, I will move on to
exploring the role for aspirin, a COX inhibitor, has in preventing cancer.
Aspirin in Cancer
Aspirin, acetylsalicylic acid, has been used by humans in its natural form, salicylic acid
from myrtle and willow, for nearly 4000 years to treat pain.

16

Aspirin acts through the

nonselective inhibition of COX enzymes thereby decreasing the formation of the inflammatory
messenger prostaglandin.

17

Now researchers are exploring new uses for aspirin beyond its

traditional uses. Joseph Sung et al. explored the use of aspirin, metformin, or a combination of
the two medications in delaying cancer onset in a retrospective cohort study. They assessed
120,971 aspirin users compared to 241, 942 nonusers from medical records in Hong Kong public
hospitals. Users had to have been prescribed aspirin for at least 6 months. They found during
their 7.5-year follow-up time that aspirin users were significantly less likely to develop
esophageal cancer.

18

This retrospective study lacked controls beyond age and sex and the

authors had no way of assessing over-the-counter use of aspirin but this data suggests further
study into aspirin as a cancer preventative is warranted.
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Two more studies assessed the use of aspirin for gastrointestinal-related metaplasia and
dysplasia. The first, by Hideki Ishikawa et al., sought to assess the effectiveness of aspirin,
mesalazine, or a combination of the two in repressing either the recurrence of polyps or
colorectal adenocarcinoma in patients with familial adenomatous polyposis. The authors
conducted a randomized, double-blinded, placebo-controlled study at 11 hospitals and outpatient
clinics in Japan. They found the aspirin treatment group had significantly reduced numbers of
polyps and exerted a protective effect against the development of atypia.

19

This study was

unfortunately very short-term, only 8 months, and only included a total of 104 patients, with 26
in the aspirin treatment group, limiting the power of generalizability. This study did use
effective controls and could be developed into a much larger and longer study to improve its
prognostic effects.
The next study takes place over 10 years and included 861 participants, overcoming the
weaknesses of the previously reviewed study. John Burn et al. conducted a 10-year follow-up of
a double-blinded, placebo-controlled study attempting to determine whether taking aspirin exerts
a protective effect against colorectal cancer in those with Lynch syndrome. They found those in
the aspirin treatment group were at a significantly reduced risk for the development of colorectal
cancer but no difference for other types of cancer outside of the gastrointestinal tract.

20

While

Lynch syndrome is an inherited condition rather than acquired, as is Barrett’s, this follow-up
study provides evidence aspirin may protect against adenocarcinomas of the gastrointestinal tract
over a prolonged period. Next, this paper will focus more specifically on adenocarcinoma of the
esophagus as it relates to Barrett’s and the use of aspirin.
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Aspirin in Barrett’s
The authors of the next study attempted to find the mechanism for how COX-1, COX-2,
and thromboxane A2 (TXA2) function in the development of Barrett’s and esophageal
adenocarcinoma. Tianshun Zhang et al. used mice with surgically created
esophagoduodenostomy anastomosis to introduce stomach acids to the esophagus in a
predictable manner creating 3 treatment groups, aspirin-treated, aspirin placebo-treated, surgical
placebo, and aspirin placebo-treated. Aspirin was given 100mg/kg once per day for 16 weeks.
Necropsy was performed at 52 weeks to obtain blood and esophageal tissue samples. Of the
surgically treated placebo group 40% developed Barrett’s, 20% developed esophageal
adenocarcinoma, and plasma showed significantly increased levels of TXA2. In the aspirin
treatment group, 31% developed Barrett’s while none developed adenocarcinoma; aspirin-treated
blood plasma showed significantly less TXA2 compared to the placebo-treated group. The
control group developed no Barrett’s and no esophageal adenocarcinoma (EAC).

21

In the same

study, the authors assessed human esophageal tissue samples from a 2012 study, Esomeprazole
and 325 mg/d Aspirin Reduce Tissue Concentrations of Prostaglandin E2 in Patients with
Barrett’s Esophagus, by Gary Falk et al. where Barrett’s esophagus patients were given various
doses of aspirin with a PPI vs placebo with a PPI.

22

Zhang et al. chose 20 random samples

from each arm of the study, 49 of the 60 samples were analyzed; 11 were not sufficiently
preserved. They found TXA2 levels were higher than the other 4 PGs measured, any dose of
aspirin + PPI significantly reduced the presence of TXA2, and Placebo +PPI did not significantly
reduce TXA2 levels.

21

This study used objective and measurable chemical markers instead of

subjective data and combined data from both mice and humans although the cells were in vitro
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rather than in vivo. This fact study lacks external validity for treatment but does point towards
future trials exploring the protective mechanism of aspirin.
A study from 2018 by Galipeau et al. used genomic sequencing of esophageal cancer
cells to help find a genetic mechanism for the development of EAC in Barrett’s and how aspirin
affects this process. All the participants were part of a larger ongoing trial called The Seattle
Barrett’s Esophagus Study. The authors chose 41 participants, from the larger trial, who had
been diagnosed with Barrett’s esophagus and met the necessary inclusion criteria. These 41
participants were called users, defined as having used an NSAID at least once per week for at
least 6 months. The 41 were matched against 41 nonusers of NSAIDS controlling for sex,
smoking status, and age within 10 years. A sample was taken from each of the participant's
esophagus in the BE segment via endoscopy. DNA was extracted and assessed for single
nucleotide variance to determine somatic mutations associated with adenocarcinoma. Data were
analyzed using a linear regression model with 6 participants (4 users and 2 non-users) assigned a
value of 0 mutations chosen based on fewer than 50 single nucleotide variances (SNVs). The
values were log-transformed. 96 somatic base substitutions were identified within the context of
nucleotide pairing while 46 of the 96 somatic SNVs had a lower mutation count in the users
compared to the nonusers.
nonusers.

23

23

3 of the 96 had a higher mutation count in users compared to

The difference in mutation load in the 96 substitutions was statistically significant

with (p<3x10-16).

23

Users were also noted to have significantly fewer mutations to the p53

gene, a tumor suppressor gene, when compared to non-users.

23

Their data suggests NSAID use

significantly reduces the mutations associated with the transformation of Barrett’s to esophageal
adenocarcinoma. The cross-section allowed for direct comparison between users and nonusers
of NSAIDs. This study was limited in the number of participants and data may be skewed due to
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participants already enrolled in another trial. The NSAID use was also self-reported rather than
controlled but they did assess objective measures in the form of SNV associated with cancers.
Unfortunately, this was also a very short duration study but follow-up is certainly available in the
future as this is an ongoing trial.
Finally, Janus Jankowski et al. published the results of their Esomeprazole and aspirin in
Barrett's oesophagus (AspECT): a randomized factorial trial in 2018 in The Lancet. The
authors sought to discover if the combination of aspirin with esomeprazole did decrease
mortality associated with esophageal adenocarcinoma in Barrett’s. This study was conducted
over 8 years with 2557 participants, all of whom had been diagnosed with Barrett’s without
EAC, high-grade dysplasia, or taking any NSAIDs at baseline. Participants were randomized
1:1:1:1 to receive esomeprazole at a high dose or low dose with or without ASA. Minimization
factors for randomization were the length of dysplasia, age, and presence or absence of intestinal
dysplasia. This study was not blinded. Participants received either 40mg esomeprazole or 20mg
esomeprazole. Each group also received 300mg of aspirin per day or no aspirin. The primary
outcomes studied were all-cause death, esophageal adenocarcinoma, or high-grade dysplasia.
They found high dose PPI by itself significantly increased time to the predetermined outcome as
compared to the sole use of low dose PPI. Aspirin compared to no aspirin showed no significant
difference but PPI with aspirin in combination showed the most difference.

24

This trial

establishes that combining high dose PPI with aspirin reduces all-cause mortality in the patient
Barrett’s esophagus during the time of the trial. Aspirin alone had no statistically significant
effect, must be in combination with PPI to show benefit. Using high dose PPI with aspirin was
better than using high dose PPI alone.
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Adverse effects of aspirin
Although aspirin has a history nearly as old as human civilization, it is not benign. Its
use in gastrointestinal cancer prevention has inherent dangers as indicated by the following.
Louise Bowman et al. studied whether giving diabetic patients aspirin 100mg per day could lead
to decreased incidence of vascular events. The primary safety outcome they also measured was
the first major bleeding event defined as intracranial hemorrhage, sight-threatening, or
gastrointestinal bleeding. They found participants in the aspirin treatment group had a 29%
greater chance of developing a major bleed, this was a significantly greater risk with the majority
of bleeds occurring in the upper GI system.

25

PPIs were used by less than 25% of participants

which may have skewed the results towards the greater incidence of GI bleeding. Further study
regarding the efficacy and safety of aspirin should include a PPI.
Joharatnam-Hogan et al. look further into the safety of aspirin in their 2019 study Aspirin
as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomized trial, in
patients who had undergone radical treatment for gastro-esophageal cancer. This blinded,
randomized trial included 2253 participants who had been diagnosed with cancer of the
esophagus, colorectal, breast, or prostate. All received 100mg of aspirin per day for 8 weeks
during a run-in period for a larger trial. 25 of the 2253 participants needed to stop the trial due to
toxicities which include esophageal pain, tinnitus, allergy, dyspepsia, bowel obstruction,
thrombocytopenia, hypertension, nausea, gastrointestinal bleed, and dizziness.

26

Although only

1% of participants reacted badly enough to remove them from the trial, aspirin can cause harm.
This is why patients must be risk stratified when considering adding aspirin as a part of Barrett’s
treatment.
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Identifying potential candidates for adding aspirin
Medication therapy is not the sole methodology in the treatment of Barrett’s esophagus.
Zhanwei Zhao et al. conducted a systematic review in 2021 of 250,157 patients with Barrett’s.
They found lifestyle changes that can reduce the risk of Barrett’s progressing to EAC include
reducing alcohol intake, weight loss, quitting smoking, and dietary changes such as increased
fiber intake.

27

Unfortunately, many patients have difficulty adhering to recommended lifestyle

modifications regardless of the risks. Xiaotao Zhang et al. conducted a prospective cohort study
with 106 recently diagnosed Barrett’s esophagus patients. The patients, recruited from the
offices of 4 different gastroenterologists, were told to stop smoking, avoid alcohol, achieve a
healthy weight, and what foods to avoid but were provided no training on how to achieve these
goals. They completed follow-up surveys at 3 and 6 months assessing lifestyle risk factors such
as weight, dietary intake, and smoking status. They also inquired about adherence determinants,
perceived benefits of therapy, perceived severity of Barrett’s, perceived risk of EAC, and
perceived barriers, to assess how likely to adhere to lifestyle changes. They found that 91% of
respondents did not meet the counseled dietary guidelines at 6 months, nor was there a
statistically significant change in any of the risk factors by 6 months even though all respondents,
in the initial survey, had high perceived benefits to lifestyle changes and risks of EAC.

28

This

was a small cohort assessed, and of the initial 106 participants, only 81 completed the 6-month
survey. This study's authors also relied on self-reporting rather than a more controlled
environment but this helps to show real-world results with patients increasing the externalizable
power. This study suggests another avenue of treatment though, patients could have daily
coaching and support groups. Respondents reported wanting to learn more about acid control
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and wanting to learn in a group atmosphere. This also suggests medication therapy is warranted
in those who struggle with lifestyle changes, 91% of patients in this study.
Patients should be risk stratified when deciding who could benefit from adding aspirin
given the aforementioned adverse effects of aspirin, especially to the gastrointestinal system
which is already compromised in Barrett’s. A 2021 study from Gastrointestinal Endoscopy
sought to identify clinical risk factors for neoplastic progression of Barrett’s in a multicenter
retrospective cohort study at Cambridge University in the UK and the Mayo Clinic in the US.
Data was collected over 10 years and included 465 patients. The authors found that the biggest
predictor for progression was the length of the segment of metaplasia with an odds ratio of 1.21
for every 1 cm of the affected esophageal segment.

29

To refine stratification, specific biomarkers and histological criteria are available and
should be used. T Kauttu et al. at Helsinki University compared cell lines from several healthy
esophagi, Barrett’s esophagi, and EAC patients to demonstrate increased expression of ADAM9
(a disintegrin and metalloproteinases). In both Barrett’s and EAC samples, compared to
controls, there with a rising trend in ADAM9 as Barrett’s progressed to EAC.

30

Likewise, Dr.

Edward Tsoi at St. Vincent’s Hospital in Melbourne was able to isolate 4 histological markers
from esophageal tissue samples from 38 Barrett’s patients who had progressed to EAC versus 17
Barrett’s patients who had not. They found that “loss of surface maturation, mucin depletion,
nuclear enlargement, and increase of mitosis” significantly predicted who would progress to
EAC if all 4 markers were present in Barrett’s esophagus histology samples.

31

Finally, Prassad

Iyer et al. assessed the use of a commercial product called TissueCypher™ in predicting the
progression of Barrett’s to EAC versus clinical variables alone. The authors pooled data from 4
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studies, defining progression as Barrett’s transforming to EAC greater than or equal to one year
after the initial diagnosis of Barrett’s esophagus. They found that 28% of samples were
progressors, the median time to progression was 38.1 months, and 79% of progression was
within 5 years of diagnosis.

32

They found TissueCypher™ to have a sensitivity of 0.38 and

specificity of 0.94 meaning this test is good at ruling out patients who will probably not progress
to EAC but may have many false negatives.

32

Interestingly, they also found that Barrett’s

length was a strong clinical predictor for transformation to EAC. This commercial test needs
refining to increase the sensitivity but, the data from this study suggests combining clinical
factors with histological tests could strongly help to risk stratify who would qualify for treatment
beyond the standard PPI, such as with aspirin.
Discussion
Although a small minority of patients will progress from Barrett’s to EAC, the survival 5year survival rate of EAC is an abysmal 20.6%, which will lead to an estimated 16,410 deaths
this year.

6

Clearly there is room for treatment modalities beyond lifestyle changes and PPIs.

De Bertoli et al. established COX inhibition may play a role in the treatment of Barrett’s by
looking at specific biomarkers, namely Ki67, cell apoptosis, and COX-2. The study was openlabel, randomized, and contained a parallel group. They evaluated 77 patients via endoscopy and
laboratory tissue analysis. Samples were taken from the esophageal-gastric junction from
patients who had a previous diagnosis of Barrett’s esophagus but no dysplasia. The two
treatment groups received either esomeprazole 40 mg bid (n=39) or pantoprazole 40 mg bid
(n=38) for 1 year. Results demonstrated a statically significant decrease in Ki67 and COX-2
expression and an increase in apoptosis for the esomeprazole group while the pantoprazole group
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showed no significant difference between baseline and trial completion.

15

While the PPI group

did demonstrate decreased COX-2 activity, there was still activity present. This study did not
involve a large number of participants, but the prospective study effectively demonstrated COX
expression plays a role in Barrett’s.
A mechanism for COX inhibition via aspirin must be explained before aspirin can be
considered. Zhang et al. provide this mechanism in their paper Targeting the COX1/2-Driven
thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma
development. This study used mice with surgically induced Barrett’s and COX-1, COX-2, and
TXA2 antibodies to show an increase in the expression of TXA2, COX-1, and COX-2. They
also showed When COX1 and COX2 were knocked out of Barrett’s and EAC cells, this resulted
in reduced cell proliferation.

21

This answers the chemical component of the PICO question but

not the treatment portion. It proposes the mechanism for how aspirin will work, the
thromboxane A2 pathway, in preventing Barrett’s esophagus from converting to EAC. It also
demonstrated providers can measure plasma levels of TXA2 to use as a marker for who might be
a candidate for ASA treatment in the presence of Barrett’s.
Jankowski et al. continued this line of research with their AspECT trial. In light of the
role COX plays in Barrett’s, they sought to answer if combining a PPI with aspirin would lead to
decreased mortality associated with EAC. This large study was conducted over 8 years. They
concluded aspirin by itself did not affect the progression of Barrett’s to EAC but aspirin in
combination with a high dose PPI regimen was more effective than high dose PPI alone in
delaying transformation and also resulted in a lower rate of all-cause mortality. The number
needed to treat with high dose PPI and aspirin was 43 in regards to preventing high-grade
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dysplasia, adenocarcinoma, or death.

24

This study suggests there is an interplay between aspirin

and a PPI that is worth at the very least further study and possibly as an adjunct to treatment.
Finally, a risk stratification strategy must be employed when considering adding aspirin
to standard PPI treatment. Several biomarkers and tissue pathologies are available, including the
commercially available TissueCypher™. Tsoi et al. continued the work of Ten et al. in verifying
4 histological criteria in predicting who will progress from Barrett’s to EAC, an important tool
given the relatively low Barrett’s to EAC progression rate.

31, 5.

Iyer et al. went beyond their

assessment of TissueCypher™ to create a 5-year risk assessment tool for progression to EAC
using TissueCypher™ in combination with several clinical factors such as age, sex, Barrett’s
segment length, and presence of a hiatal hernia.

32

This tool could help identify participants for

a much larger study investigating the power of aspirin combined with a proton pump inhibitor to
not only arrest the transformation of Barrett’s to esophageal adenocarcinoma but possibly reverse
the dysplastic changes seen in Barrett’s.
We suggest some further studies may be needed to clarify the benefits of adding aspirin
in the chemoprevention of EAC in the presence of Barrett’s esophagus. We propose a 5-year
study with two goals. The first is to assess the effectiveness of the Iyer et. risk assessment tool.
32

The second is to specifically assess the effectiveness of aspirin in preventing the progression

of Barrett’s esophagus, and the potential dose that would be most effective. We propose a
randomized, double-blinded, placebo-controlled study over a 5-year period wherein participants
with Barrett’s esophagus are given both PPI and either placebo or aspirin at various doses.
Participants will receive follow-up endoscopies at years 1, 3, and 5 of the trial to assess for
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progression in each of the groups. This study could further demonstrate the potential role for
aspirin in Barrett’s esophagus.
Conclusion
This analysis sought to clarify the use of aspirin as adjunctive therapy in the treatment of
Barrett’s esophagus. It began with the PICO question
P: Patients with Barrett’s esophagus not yet esophageal adenocarcinoma
I: Standard PPI treatment with the addition of Aspirin
C: Standard PPI treatment only
O: Prevention of progression of Barrett’s esophagus to esophageal adenocarcinoma
To do this we investigated how prostaglandins and COX are associated with cancer development
and how a COX inhibitor, such as aspirin, may be of therapeutic use.
COX has been demonstrated to be a factor in the transformation of Barrett’s to EAC.
While PPI treatment alone is effective for some, many patients progress to adenocarcinoma
placing a burden on an already taxed medical system. Aspirin is an inexpensive and readily
available medication with notable but relatively few adverse effects when used appropriately
with the appropriate patient population. There are several methods available to determine which
Barrett’s patients are likely to progress to EAC. Using clinical factors, histological criteria,
plasma markers, or commercial devices can help risk stratify who would most benefit from
adding aspirin to PPI treatment. Further, longer-term prospective human trials investigating the
PPI aspirin combination are certainly warranted. This combination could be the stopgap needed
to prevent EAC for many patients.

Speakman 22

References
1. Spechler MD SJ. Barrett’s Esophagus: Epidemiology, Clinical Manifestations, and
Diagnosis - UpToDate.; 2021. Accessed July 3, 2022. https://www-uptodatecom.ezproxy.augsburg.edu/contents/barretts-esophagus-epidemiology-clinicalmanifestations-anddiagnosis?search=barrett%20esophagus&source=search_result&selectedTitle=1~120&usage
_type=default&display_rank=1
2. Kahrilas MD PJ. Complications of Gastroesophageal Reflux in Adults - UpToDate. Jan 14,
2022 Accessed July 3, 2022. https://www-uptodatecom.ezproxy.augsburg.edu/contents/complications-of-gastroesophageal-reflux-inadults?search=barrett%27s%20esopphagus%20GERD&source=search_result&selectedTitle
=2~150&usage_type=default&display_rank=2
3. SINGH T, SANGHI V, THOTA PN. Current management of Barrett esophagus and
esophageal adenocarcinoma. Cleve Clin J Med. 2019;86(11):724-732.
doi:10.3949/ccjm.86a.18106
4. Digestive Diseases Statistics for the United States | NIDDK. National Institute of Diabetes
and Digestive and Kidney Diseases. Accessed July 3, 2022.
https://www.niddk.nih.gov/health-information/health-statistics/digestive-diseases
5. Kroep S, Lansdorp-Vogelaar I, Rubenstein JH, et al. AN ACCURATE CANCER
INCIDENCE IN BARRETT’S ESOPHAGUS: A BEST ESTIMATE USING PUBLISHED
DATA AND MODELING. Gastroenterology. 2015;149(3):577-585.e4.
doi:10.1053/j.gastro.2015.04.045
6. Cancer of the Esophagus - Cancer Stat Facts. SEER. Accessed March 25, 2022.
https://seer.cancer.gov/statfacts/html/esoph.html
7. Kuipers EJ. Barrett Esophagus and Life Expectancy: Implications for Screening?
Gastroenterol Hepatol (N Y). 2011;7(10):689-691.
8. Ricciotti E, FitzGerald GA. Prostaglandins and Inflammation. Arterioscler Thromb Vasc
Biol. 2011;31(5):986-1000. doi:10.1161/ATVBAHA.110.207449
9. Wang X, Baek SJ, Eling T. COX inhibitors directly alter gene expression: role in cancer
prevention? Cancer Metastasis Rev. 2011;30(0):641-657. doi:10.1007/s10555-011-9301-4
10. Alkhayyat M, Kumar P, Sanaka KO, Thota PN. Chemoprevention in Barrett’s esophagus and
esophageal adenocarcinoma. Therap Adv Gastroenterol. 2021;14:17562848211033730.
doi:10.1177/17562848211033730

Speakman 23
11. Falk GW. Barrett’s oesophagus: Frequency and prediction of dysplasia and cancer. Best
Practice & Research Clinical Gastroenterology. 2015;29(1):125-138.
doi:10.1016/j.bpg.2015.01.001
12. Nathan C. Points of control in inflammation. Nature. 2002;420(6917):846-852.
doi:10.1038/nature01320
13. Wong CC, Kang W, Xu J, et al. Prostaglandin E2 induces DNA hypermethylation in gastric
cancer in vitro and in vivo. Theranostics. 2019;9(21):6256-6268. doi:10.7150/thno.35766
14. Majka J, Wierdak M, Szlachcic A, et al. Interaction of epidermal growth factor with COX-2
products and peroxisome proliferator-activated receptor-γ system in experimental rat
Barrett’s esophagus. American Journal of Physiology-Gastrointestinal and Liver Physiology.
2020;318(3):G375-G389. doi:10.1152/ajpgi.00410.2018
15. de Bortoli N, Martinucci I, Piaggi P, et al. Randomised clinical trial: twice daily
esomeprazole 40 mg vs. pantoprazole 40 mg in Barrett’s oesophagus for 1 year. Alimentary
Pharmacology & Therapeutics. 2011;33(9):1019-1027. doi:10.1111/j.13652036.2011.04616.x
16. The Story of Aspirin | The International Aspirin Foundation. Aspirin Foundation. Accessed
July 20, 2022. https://www.aspirin-foundation.com/history/the-aspirin-story/
17. Aspirin: Drug information - UpToDate. Accessed July 20, 2022. https://www-uptodatecom.ezproxy.augsburg.edu/contents/aspirin-druginformation?search=aspirin&source=panel_search_result&selectedTitle=1~148&usage_type
=panel&kp_tab=drug_general&display_rank=1#F137053
18. Sung JJ, Ho JM, Lam AS, Yau ST, Tsoi KK. Use of metformin and aspirin is associated with
delayed cancer incidence. Cancer Epidemiology. 2020;69:101808.
doi:10.1016/j.canep.2020.101808
19. Ishikawa H, Mutoh M, Sato Y, et al. Chemoprevention with low-dose aspirin, mesalazine, or
both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP
Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial. Lancet
Gastroenterol Hepatol. 2021;6(6):474-481. doi:10.1016/S2468-1253(21)00018-2
20. Burn J, Sheth H, Elliott F, et al. Cancer prevention with aspirin in hereditary colorectal
cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2
study: a double-blind, randomised, placebo-controlled trial. Lancet. 2020;395(10240):18551863. doi:10.1016/S0140-6736(20)30366-4
21. Zhang T, Wang Q, Ma WY, et al. Targeting the COX1/2-Driven thromboxane A2 pathway
suppresses Barrett’s esophagus and esophageal adenocarcinoma development.
EBioMedicine. 2019;49:145-156. doi:10.1016/j.ebiom.2019.10.038

Speakman 24
22. Falk GW, Buttar NS, Foster NR, et al. Esomeprazole and 325 mg/d Aspirin Reduce Tissue
Concentrations of Prostaglandin E2 in Patients with Barrett’s Esophagus. Gastroenterology.
2012;143(4):917-926.e1. doi:10.1053/j.gastro.2012.06.044
23. Galipeau PC, Oman KM, Paulson TG, et al. NSAID use and somatic exomic mutations in
Barrett’s esophagus. Genome Medicine. 2018;10:1-1. doi:10.1186/s13073-018-0520-y
24. Jankowski JAZ, de Caestecker J, Love SB, et al. Esomeprazole and aspirin in Barrett’s
oesophagus (AspECT): a randomised factorial trial. Lancet. 2018;392(10145):400-408.
doi:10.1016/S0140-6736(18)31388-6
25. ASCEND Study Collaborative Group, Bowman L, Mafham M, et al. Effects of Aspirin for
Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med. 2018;379(16):15291539. doi:10.1056/NEJMoa1804988
26. Joharatnam-Hogan N, Cafferty F, Hubner R, et al. Aspirin as an adjuvant treatment for
cancer: feasibility results from the Add-Aspirin randomised trial. Lancet Gastroenterol
Hepatol. 2019;4(11):854-862. doi:10.1016/S2468-1253(19)30289-4
27. Zhao Z, Yin Z, Zhang C. Lifestyle interventions can reduce the risk of Barrett’s esophagus: a
systematic review and meta‐analysis of 62 studies involving 250,157 participants. Cancer
Med. 2021;10(15):5297-5320. doi:10.1002/cam4.4061
28. Zhang X, Anandasabapathy S, Abrams J, Othman M, Badr HJ. Lifestyle Risk Factors,
Quality of Life, and Intervention Preferences of Barrett’s Esophagus Patients: A Prospective
Cohort Study. Glob Adv Health Med. 2021;10:21649561211001344.
doi:10.1177/21649561211001346
29. Phillips R, Januszewicz W, Pilonis ND, et al. The risk of neoplasia in patients with Barrett’s
esophagus indefinite for dysplasia: a multicenter cohort study. Gastrointestinal Endoscopy.
2021;94(2):263-270.e2. doi:10.1016/j.gie.2021.01.042
30. Kauttu T, Mustonen H, Vainionpää S, et al. Disintegrin and metalloproteinases (ADAMs)
expression in gastroesophageal reflux disease and in esophageal adenocarcinoma. Clin
Transl Oncol. 2017;19(1):58-66. doi:10.1007/s12094-016-1503-3
31. Tsoi EH, Williams RA, Christie M, et al. Not all low grade dysplasia in Barrett’s oesophagus
is the same: using specific histological criteria in predicting progression to neoplasia.
Pathology. 2021;53(6):700-704. doi:10.1016/j.pathol.2021.06.116
32. Iyer PG, Codipilly DC, Chandar AK, et al. Prediction of Progression in Barrett’s Esophagus
Using a Tissue Systems Pathology Test: A Pooled Analysis of International Multicenter
Studies. Clinical Gastroenterology and Hepatology. Published online February 22, 2022.
doi:10.1016/j.cgh.2022.02.033

Augsburg University Institutional Repository Deposit Agreement
By depositing this Content (“Content”) in the Augsburg University Institutional Repository known as Idun, I agree
that I am solely responsible for any consequences of uploading this Content to Idun and making it publicly available,
and I represent and warrant that:
●

I am either the sole creator or the owner of the copyrights in the Content; or, without obtaining another’s
permission, I have the right to deposit the Content in an archive such as Idun.
● To the extent that any portions of the Content are not my own creation, they are used with the copyright
holder’s expressed permission or as permitted by law. Additionally, the Content does not infringe the
copyrights or other intellectual property rights of another, nor does the Content violate any laws or
another’s right of privacy or publicity.
● The Content contains no restricted, private, confidential, or otherwise protected data or information that
should not be publicly shared.
I understand that Augsburg University will do its best to provide perpetual access to my Content. To support these
efforts, I grant the Board of Regents of Augsburg University, through its library, the following non-exclusive,
perpetual, royalty free, worldwide rights and licenses:
●

To access, reproduce, distribute and publicly display the Content, in whole or in part, to secure, preserve
and make it publicly available
● To make derivative works based upon the Content in order to migrate to other media or formats, or to
preserve its public access.
These terms do not transfer ownership of the copyright(s) in the Content. These terms only grant to Augsburg
University the limited license outlined above.

Initial one:
JS I agree and I wish this Content to be Open Access.
___
___ I agree, but I wish to restrict access of this Content to the Augsburg University
network.
Work (s) to be deposited
Title: _______________________________________________________
A Role for COX Inhibition in the Prevention of Progression of Barrett's Esophagus to EAC
John Speakman
Author(s) of Work(s): ___________________________________________
John Speakman
Depositor’s Name (Please Print): ___________________________________
07/11/2022
Author’s Signature: ______________________________ Date: _________
If the Deposit Agreement is executed by the Author’s Representative, the Representative shall separately execute the
Following representation.
I represent that I am authorized by the Author to execute this Deposit Agreement on the behalf of the Author.

Author’s Representative Signature: ___________________ Date: ________

